Conrad M Tobert1, Kenneth G Nepple2, Bradley D McDowell3, Mary E Charlton3, Sarah L Mott3, Thomas S Gruca4, Laura Quast1, Bradley A Erickson5. 1. University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA. 2. University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA; University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. 3. University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. 4. University of Iowa, Tippie College of Business, Iowa City, IA. 5. University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA. Electronic address: brad-erickson@uiowa.edu.
Abstract
OBJECTIVE: To identify factors associated with nonmuscle invasive bladder cancer (NMIBC) American Urological Association (AUA) guideline compliance in a rural state, to evaluate compliance rates over time, and to assess the impact of patient and provider rurality on delivery of NMIBC care. METHODS: We identified 847 Iowans in Surveillance, Epidemiology, and End Results-Medicare from 1992 to 2009 with high-grade NMIBC who survived 2 years and were not treated with cystectomy or radiation during this period. Compliance with AUA guidelines was assessed over time and compared to patient demographic, tumor, and treatment institution variables. Impact of rurality was analyzed using Surveillance, Epidemiology, and End Results ZIP code data travel distance of patient to nearest urologist practice location. RESULTS: Overall compliance with AUA guidelines was low (<1%), and did not markedly improve over the study period. In the multivariable model, only care at an academic medical center (OR 11.68, 95% CI 7.07-19.29) and tumor stage (Tis; OR 3.24, 95% CI 1.86-5.63) increased the odds of compliance. Patients living closer (<10 miles) to their urologists underwent more cystoscopies than patients living further (>30 miles) but distance did not affect compliance with other measures. Compliance was not associated with cancer-specific survival. CONCLUSION: Compliance with post-Transurethral Resection of Bladder Tumor (TURBT) NMIBC treatment guidelines has improved but remains suboptimal in our rural state, and is highly associated with treatment at an academic cancer center for reasons that could not be fully explained with these data.
OBJECTIVE: To identify factors associated with nonmuscle invasive bladder cancer (NMIBC) American Urological Association (AUA) guideline compliance in a rural state, to evaluate compliance rates over time, and to assess the impact of patient and provider rurality on delivery of NMIBC care. METHODS: We identified 847 Iowans in Surveillance, Epidemiology, and End Results-Medicare from 1992 to 2009 with high-grade NMIBC who survived 2 years and were not treated with cystectomy or radiation during this period. Compliance with AUA guidelines was assessed over time and compared to patient demographic, tumor, and treatment institution variables. Impact of rurality was analyzed using Surveillance, Epidemiology, and End Results ZIP code data travel distance of patient to nearest urologist practice location. RESULTS: Overall compliance with AUA guidelines was low (<1%), and did not markedly improve over the study period. In the multivariable model, only care at an academic medical center (OR 11.68, 95% CI 7.07-19.29) and tumor stage (Tis; OR 3.24, 95% CI 1.86-5.63) increased the odds of compliance. Patients living closer (<10 miles) to their urologists underwent more cystoscopies than patients living further (>30 miles) but distance did not affect compliance with other measures. Compliance was not associated with cancer-specific survival. CONCLUSION: Compliance with post-Transurethral Resection of Bladder Tumor (TURBT) NMIBC treatment guidelines has improved but remains suboptimal in our rural state, and is highly associated with treatment at an academic cancer center for reasons that could not be fully explained with these data.
Authors: M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer Journal: J Urol Date: 2007-12 Impact factor: 7.450
Authors: Robert S Svatek; Brent K Hollenbeck; Sten Holmäng; Richard Lee; Simon P Kim; Arnulf Stenzl; Yair Lotan Journal: Eur Urol Date: 2014-01-21 Impact factor: 20.096
Authors: Jorg Oddens; Maurizio Brausi; Richard Sylvester; Aldo Bono; Cees van de Beek; George van Andel; Paolo Gontero; Wolfgang Hoeltl; Levent Turkeri; Sandrine Marreaud; Sandra Collette; Willem Oosterlinck Journal: Eur Urol Date: 2012-11-02 Impact factor: 20.096
Authors: Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; George G Klee; Michael M Lieber; Steven J Jacobsen Journal: Am J Epidemiol Date: 2011-03-02 Impact factor: 4.897
Authors: Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin Journal: Cancer Date: 2011-08-05 Impact factor: 6.860
Authors: Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan Journal: J Urol Date: 2016-06-16 Impact factor: 7.450
Authors: Marina Deuker; L Franziska Stolzenbach; Claudia Collà Ruvolo; Luigi Nocera; Zhe Tian; Frederik C Roos; Andreas Becker; Luis A Kluth; Derya Tilki; Shahrokh F Shariat; Fred Saad; Felix K H Chun; Pierre I Karakiewicz Journal: Cancer Causes Control Date: 2020-11-23 Impact factor: 2.506
Authors: Kelly K Bree; Yong Shan; Patrick J Hensley; Niyati Lobo; Chengrui Hu; Douglas S Tyler; Karim Chamie; Ashish M Kamat; Stephen B Williams Journal: JAMA Netw Open Date: 2022-03-01